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FRONTIERS IN PRECISION MEDICINE II: 
CANCER, BIG DATA AND THE PUBLIC 
 




Emily Coonrod, Jorge L. Contreras, Willard Dere, Jeffrey Botkin, Leslie P. 
Francis, James Tabery1 
 
 In a December 2016 interview with Bloomberg BNA, Dr. Francis Collins, 
Director of the U.S. National Institutes of Health, predicted that precision 
medicine “is going to change everything about how we understand health and 
disease.”2  The massive Precision Medicine Initiative (PMI), now re-named the 
“All of Us” Research Program, plans to study a cohort of more than one million 
Americans. Its hope is to expand our understanding of heredity and disease and 
revolutionize the treatment of disease and the improvement of human health.  
 
 According to the White House, precision medicine is “health care tailored 
for you.”3  At its most fundamental level, precision medicine seeks to optimize 
treatments based on individual physiological characteristics, such as the ability to 
metabolize certain compounds or to respond to one or another set of drugs 
based on individual differences in genes, environments, and lifestyles. 
 
 Precision medicine is being developed today within a complex landscape 
of medicine, science, public policy, law, and ethics. In December 2016, the 
University of Utah School of Medicine, Huntsman Cancer Institute and S.J. 
Quinney College of Law held their second annual symposium on current issues 
in precision medicine. This year, the focus of symposium was on cancer and how 
precision medicine can enlist “big data” to combat what has been termed “the 
emperor of all maladies” -- cancer.4 
 
 This two-day event convened national experts in genetics, medicine, 
bioinformatics, intellectual property, health communications and bioethics to 
discuss and debate many of the pressing questions raised by precision medicine 
																																																								
1 The authors thank Jacqueline Etsy Morrison and Jessica Van Wagoner for their assistance in 
the preparation of this report, and acknowledge Julie Kiefer, Kristina Monty, Jacqueline Etsy 
Morrison, Melinda Rogers, Samantha Weeks, Dana Wilson, Jonelle White and the 2016-17 
Fellows of the Center for Law and Biomedical Sciences for their invaluable support in planning 
and executing this conference. 
2  Jeannie Baumann, NIH’s Collins: Precision Medicine Will Change ‘Everything’, BNA Life 
Sciences Law & Indus. Report, Jan. 6, 2017. 
3 White House. The Precision Medicine Initiative, https://www.whitehouse.gov/precision-medicine. 
4 Siddhartha Mukherjee, The Emperor of All Maladies: A Biography of Cancer (New York: 
Scribner, 2010). 
 Electronic copy available at: https://ssrn.com/abstract=3074961 
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as it relates to cancer research. 5  The key arguments, conclusions and 
unresolved issues that emerged from the symposium are summarized in these 
proceedings. Speakers and participants are referred to by name in the text, with 
the full conference agenda and speaker names and affiliations in the Appendix. 
 
1. Tackling Cancer With Precision Data 
 
a.  The Science Of Precision Oncology 
 
The first session of the Frontiers in Precision Medicine II: Cancer, Big 
Data and the Public conference hosted by the University of Utah explored issues 
facing successful clinical implementation of precision medicine in oncology. Ana 
Maria Lopez introduced this session and kicked off the symposium. She 
described the elements that will ensure the success of precision medicine 
including a team science approach, data sharing policies, insurance coverage, 
and inclusive patient engagement. She stressed the importance of patient 
engagement and warned that without it, clinical outcomes for diverse 
communities may worsen and health disparities may grow. When an inclusive 
approach to precision medicine is taken, these concepts can be applied to public 
health to stratify risk at the population level and improve prevention and 
treatment with targeted strategies that will ultimately lead to disease prevention, 
health promotion, and health inequity reduction. 
  
Following Dr. Lopez’s introduction, Kathleen Cooney provided an overview 
of precision oncology and discussed specific approaches to its implementation in 
clinical care.  Dr. Cooney noted that cancer is a common disease with 1.7 million 
newly diagnosed cases per year and is responsible for 600,000 deaths per year 
in the United States.  In addition, the cost of cancer care is predicted to balloon to 
$170 billion per year by 2020 due to an increasingly aging population and the 
increasing costs of new cancer therapies. The evolving recognition of cancer as 
a genetic disease that can be caused by both germline mutations (mutations in 
every cell of the body that can be passed on to one’s children) and somatic 
mutations (mutations that develop in certain cells in the body that are not passed 
on to one’s children) has made the practice of precision oncology a reality. The 
practice of precision oncology is reliant on new technology that rapidly generates 
sequencing data on all genes in tumor and non-tumor cells from cancer patients. 
Dr. Cooney pointed out that early successes with therapies targeted to specific 
mutations serve as a proof of principle that this approach works, although 
responses are not always sustained. In addition, these therapies are expensive, 
																																																								
5 Video recordings of the entire symposium, as well as slide presentations made by certain 
speakers, can be accessed at http://law.utah.edu/projects/precision-medicine/frontiers-in-
precision-medicine-2016-cancer-big-data-and-the-public/.  Proceedings of the University of Utah’s 
first annual precision medicine symposium, “Frontiers in Precision Medicine: Exploring Science 
and Policy Boundaries” can be found at 
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2851946. 
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have unique side effects, and can contribute to the development of drug resistant 
tumors. These discoveries demonstrate the significant impact that the 
implementation of precision oncology can have on both individual patients and 
public health, as discussed earlier by Dr. Lopez.   
 
Although targeted therapies can be successful, they have uncovered new 
challenges to patient care. Without a systematic approach to identifying 
actionable mutations, many may be unable to access new therapies. The 
Princess Margaret IMPACT/COMPACT trial, a large study with 1,640 
participants, revealed that only 15% of patients in the study were ultimately 
enrolled in clinical trials and only 5% were enrolled in clinical trials for a drug that 
was targeted to their specific genetic diagnosis.6 This study made clear that 
routinely matching therapies to actionable mutations is another hurdle to 
overcome in the implementation of precision oncology in the clinical setting. 
 
Dr. Cooney described a multi-disciplinary, team approach to precision 
oncology, the MI-ONCOSEQ (Michigan Oncology Sequencing Center). In this 
model, the patient first meets with both a medical oncologist and a genetic 
counselor and provides informed consent.  A biopsy of the tumor is then obtained 
along with a saliva or blood sample.  DNA is extracted from the biological 
specimens and sequenced. Genomic data are analyzed and a Precision 
Medicine Tumor Board meets to determine if results can inform the patient’s 
clinical treatment and if there are additional findings that will impact the patient’s 
health. The Precision Medicine Tumor Board is composed of experts in clinical 
oncology, genomics, bioinformatics, pathology, clinical genetics, and bioethics. A 
patient advocate serves on this Board to ensure inclusion of the patient 
perspective in the decision-making process. Results are returned to the patient 
by both the genetic counselor and the medical oncologist. Dr. Cooney then 
illustrated success stories from the MI-ONCOSEQ project describing patients 
with medically actionable mutations that responded extremely well to the 
targeted, molecularly matched treatment recommended by the Tumor Board. In 
summary, although the genetic cause of cancer can now be identified, doing so 
requires a multidisciplinary, team based approach.  
 
Dr. Scott Tomlins closed the session with a presentation exploring the 
“hype versus reality” of precision oncology and reinforced some of Dr. Cooney’s 
comments.  Dr. Tomlins noted that identifying medically actionable mutations in 
cancer patients is not sufficient to drive clinical choices for cancer care. What 
really matters when moving precision oncology to the clinic is determining how 
many patients are enrolled in clinical trials based on their sequencing results and 
how many of these patients have a favorable response to therapy. Dr. Tomlins 
used the same example mentioned by Dr. Cooney from the IMPACT/COMPACT 
																																																								
6 Tracey L. Stockley et al. Molecular profiling of advanced solid tumors and patient outcomes with 
genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial, 8 Genome 
Medicine 109, Oct. 25, 2016. 
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trial7 to illustrate that not every patient is benefitting from sequencing and that the 
field needs to study further the clinical utility of sequencing for patient care and 
clinical outcomes. Some large studies are beginning to tackle this by enrolling 
patients at multiple centers around the country and matching patients with a 
specific drug based on their genetic results.  In this approach, patients are not 
treated by the anatomical type of cancer they have (e.g., lung, colon, breast), but 
rather by the mutation causing their cancer. Although this approach will get us 
closer to understanding patient outcomes, there are still barriers to doing this on 
a very large scale. The cost of sequencing a large number of people is still high 
and new therapies are approved for treatment of a specific type of cancer rather 
than a molecular signature, meaning that pharmaceutical companies will 
encounter regulatory barriers to drug approval using this approach. Dr. Tomlins 
also pointed out that there are a number of genes known to cause a high 
percentage of cancers that have been recalcitrant to therapeutic targeting, such 
as TP53, KRAS, MYC, APC, CTNNB1, and PIK3CA.  New approaches to drug 
development will be necessary to target the genes that are responsible for many 
cancer cases.  Lastly, Dr. Tomlins predicts that immunotherapy will have the 
most impact on clinical outcomes because sequencing allows for the creation of 
an antigen specific to the patients’ tumor that will be attacked by their own 
immune system. To summarize, Dr. Tomlins urges the field to move beyond 
sequencing to understand clinical utility. This requires improving enrollment of 
patients into matched clinical trials and systematically measuring outcomes. 
 
b.  The Challenges Of Big Data 
 
New and innovative informatics approaches are necessary to unlock the 
promise of precision medicine in clinical practice, but working with the large 
datasets produced by next generation sequencing poses a number of challenges 
being tackled at institutions around the country. Dr. Rakesh Nagarajan described 
the convergence of three major innovations that have led to the rapid emergence 
of precision medicine.  First is the development of the technology to do massively 
parallel sequencing with a cost that continues to decrease. Second is a dramatic 
increase in medical knowledge-bases enables the interpretation of this 
sequencing data to inform clinical practices, such as prescribing targeted drugs 
and immunotherapies. Third are advances in information management and 
informatics that are bridging the production of sequencing data and medical 
knowledge to make precision medicine possible. There remain a number of 
barriers to truly conducting precision medicine at scale to sustain the current 
exponential growth of DNA sequencing.  At a high level, these barriers include 
acquisition of the data, data storage solutions, distribution of data on a population 
scale, and analysis capabilities.8  
																																																								
7	Id. 
8 Zachary D. Stephens et al, Big Data: Astronomical or Genomical? 13 PLoS Biology, July 7, 
2015. 
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Changing the infrastructure of the electronic health record (EHR) is one way 
that informatics is being used to address these barriers.  The EHR at Washington 
University in St Louis School of Medicine alone contains records from ~5.7 
million patients with ~40 million encounters, and contains ~89 million text 
documents with ~48 million scanned documents. The vast majority of the 
genomic data that is produced clinically is found in text documents. This creates 
a major informatics problem because it is difficult to electronically extract 
information from free text due to inconsistencies in ontologies and vocabulary 
standards. Therefore, a test result and its details are not recorded in the EHR in 
a way that can be easily extracted and used to treat the patient.  An informatics 
solution has already been put in place for transferring different types of non-
genomic data from disparate sources to the EHR using HL7 messaging to 
transfer and store demographic information, laboratory results, and medication 
prescribing information in a standardized way. There are now informatics 
solutions being developed to achieve the same goal with genomic data. One 
example is the HL7 specification Clinical Genomics Object Model to transmit 
genomic results as discrete fields.9 However, this standard has not been adopted 
by EHR vendors due to low demand.  Additional file formats being standardized 
for this purpose are CRAM, BAM/SAM, VCF/BCF and HGVS for variant 
nomenclature.  
 
Biomedical knowledge-bases are significant resources used by clinical 
laboratories to classify variants and determine if variants are clinically actionable. 
These knowledge-bases are continuously expanding. However, in order to be 
useful, the laboratory and knowledge-base must be using the same human 
genome build to annotate variants or have the capability to map variants from 
one genome build to another accurately and automatically.  There are guidelines 
published to organizations such as the American Society of Clinical Oncology 
and the FDA, along with medical publications and clinical trial studies, but these 
sources are also free text. Oncology Research Sources such as COSMIC, 
TCGA, and cBioPortal are available in knowledge-bases to help guide clinical 
laboratory interpretations, as are clinical variant databases such as ClinVar, 
Emory, ARUP Laboratories, and Invitae. All of these resources aid clinical 
interpretation, but pose some of the same challenges described above. 
 
PierianDx has begun to address these problems by creating a network of 
thirteen laboratories offering somatic cancer panels clinically. This laboratory 
network is conducting clinical tests with 41 different gene panels having an 
average panel size of 44 genes.  Through this network, PierianDx has been 
integrating information from the sources described above to create a curated 
knowledge-base for these network laboratories. Genes on panels offered through 
																																																								
9 Roy Somak, et al, Next-Generation Sequencing Informatics: Challenges and Strategies for 
Implementation in a Clinical Environment, 140 Arch. Pathol. Lab. Med. 958, Sept. 2016. 
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this network have been curated with FDA drug label information, National 
Comprehensive Cancer Network guidelines, clinically relevant interpretations, 
associated clinical trials, and clinical associations. Creating this community 
knowledgebase allows PierianDx and its network to aggregate results to better 
understand the genetic basis of cancers such as mutation frequency by tumor 
type.  
 
This network approach begins to address some of the current informatics 
issues, and is already being performed nationally in health care systems such as 
the VA’s Precision Oncology Program, which is an integrated database with 
clinical, genomic, imaging, and research data processed and analyzed through 
Natural Language Processing (NLP).10  The evolution of these networks will 
ultimately create a national learning healthcare system, which integrates genomic 
data, prior patient data, and population health data to deliver the best, most 
appropriate care possible in the era of genomic medicine. Standards such as 
FHIR, a data specification that allows sharing of data formats across 
organizations, and the meaningful use-stage 3 program from the Centers for 
Medicaid and Medicare Services114 requiring electronic delivery of care records 
when patients transition from one hospital organization to another are major 
steps toward creating this national network. Current technologies also enable a 
disruptive approach to current care delivery by enabling patients to drive their 
own healthcare delivery by having access to their individual, comprehensive 
electronic medical record and being an active and engaged member of the 
healthcare delivery team.12  
 
The second half of the session highlighted systems put in place at the 
University of Utah’s Huntsman Cancer Institute (HCI) to deliver precision 
medicine. Samir Courdy described the evolution of the informatics infrastructure 
at HCI since 1999.  Building the capability for delivery of precision medicine 
began with a redesign of the IT architecture to enable database technologies and 
web capabilities for infrastructure applications. The next phase of pipeline 
development from 2002-2006 focused on building the missing links to enable 
patient education, research, and delivery of care such as creating a research 
subject registry and integration with the University of Utah Hospital’s Enterprise 
Data Warehouse (EDW). 2006-2010 was a period of customization, expansion, 
and increased efficiencies while building the critical infrastructure for NLP.  
Currently, the infrastructure is being expanded to allow for integration of 
disparate data sets, collaboration with other institutions, and management of big 
data.  Like Dr. Nagarajan, Mr. Courdy also pointed out that one of the major 
challenges to integration of genomic data into clinical care is our ability to mine 
																																																								
10	http://www.blogs.va.gov/VAntage/22165/va-precision-oncology/. Accessed 6/2/17. 
11	https://www.cms.gov/Regulations-and 
Guidance/Legislation/EHRIncentivePrograms/Stage3Medicaid_Require.html. Accessed 6/2/17. 
12	http://slideplayer.com/slide/9984919/. Accessed 6/2/17. 
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data from free text.  Mr. Courdy predicts that this problem will continue to exist 
into the foreseeable future, as clinical laboratories are designed to communicate 
results via free text. However, this problem creates opportunities for innovation 
and research into NLP and machine learning.   
 
HCI has created a solution for implementing precision medicine termed the 
Research Informatics Shared Resource (RISR). This pipeline utilizes both 
commercial and non-commercial components to create an information network 
that pulls data from the different testing laboratories used by HCI, primarily 
Foundation Medicine and the University of Utah’s ARUP Laboratories, into a 
research integration engine allowing this data to be deposited into the EHR, the 
EDW, and shared with national oncology research networks as appropriate. HCI 
is working with testing laboratories to solve the problem of receiving genomic 
results in free text format.  Foundation Medicine and ARUP Laboratories are now 
providing testing data in PDF, BAM, VCF, and/or XML file formats, and HL7 
messaging is being used by Foundation Medicine to deposit test results into the 
University’s EHR.  The HCI team is utilizing commercially available and in-house 
developed tools for NLP to turn free text reports into discrete, searchable, and 
structured data elements that can be utilized by HCI’s research integration 
engine. 
 
Dr. David Nix next discussed his team’s approach to move clinical genomic 
samples into a translational research program. There are two types of genomic 
data received by HCI, data generated on samples through research, and data 
generated on samples through CLIA laboratories from clinical tests. HCI recently 
joined the ORIEN network, which aims to leverage multiple data sources from 
different institutions to better match patients to targeted treatments.  HCI has 
implemented the Total Cancer Care protocol, a study whose data is shared with 
the ORIEN network. This protocol provides a uniform patient consent form, an 
umbrella IRB at each institution to allow data access across institutions, and has 
put in place a variety of data sharing mechanisms that allows access to both 
clinical and molecular data. Foundation Medicine is the preferred clinical testing 
vendor for HCI, because its data is rich and focused on clinical utility, making it 
useful for sharing within HCI’s research network. Foundation Medicine’s tests 
target clinically actionable genes from tumors in two different gene panel tests 
that detect short variants (SNVs and INDELs), copy number variants, and select 
gene rearrangements. Importantly, the data are returned to HCI in discrete field 
XML clinical reports and unfiltered BAM file formats. These data are then re-
processed before being moved into Mr. Courdy’s pipeline.  In order to make 
these clinical data useful for a research program, it is imperative to pull out all of 
the information from the tests, rather than accessing only the information that is 
in the clinical report. Dr. Nix’s team has created a pipeline to re-process the data 
from the unfiltered BAM files to normalize the variant calls from different 
companies and sources in order to unify the datasets and increase their utility for 
research. There are a number of challenges inherent in the re-processing that 
are being addressed.  First, the output from the re-processing pipeline does not 
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always result in the exact same variants called in the clinical laboratory’s reports. 
This is due to differences in variant calling and annotation between the two 
pipelines. Therefore, it is critical to develop and maintain best practices for the 
pipeline, implement as much pipeline automation as possible, and develop NLP 
tools to extract data from free text clinical reports.  Dr. Nix asked the audience to 
consider using drop down menus and ontologies for phenotypic and clinical data 
management to help relieve the free text extraction problem.   
 
The pipeline created by HCI utilizes a mixture of commercial and open source 
tools, and the team is now focusing on scaling up this pipeline to handle the 
deluge of additional data that will be coming to HCI when insurance companies 
begin to more routinely reimburse for genetic panel testing in oncology, thus 
creating much larger data sets than are currently being managed. 
 
c.  Precision Prevention 
 
The next session focused on the topic of precision prevention and featured 
discussions on current approaches in the areas of colorectal cancer and lung 
cancer. The session was moderated by Dr. Cornelia Ulrich. Dr. Ulrich defined 
precision prevention as “tailoring of preventive strategies more precisely, for 
example by genetic markers, molecular markers, or overall risk prediction.”  
Taking this approach to cancer prevention can maximize the use of resources 
and identify specific prevention approaches for groups that will receive the most 
benefit.  Dr. Ulrich then described her group’s work in exploring the use of aspirin 
in colorectal cancer prevention. Aspirin has been shown to reduce the number of 
polyps in patients with colorectal cancer, has shown an inverse association with 
colorectal cancer and other tumor types in epigenetic studies, and the molecular 
pathway affected by aspirin is known. In addition, long term use (10-14 years) of 
aspirin at a low dose has been shown to be protective against colorectal 
cancer. 13   Although the findings that support the use of aspirin to prevent 
colorectal cancer are strong, there are major risks to long term aspirin use, 
including GI symptoms and serious bleeding. One way to mitigate these risks is 
to tailor the recommendations for long term aspirin use to populations who will 
benefit the most while reducing the risk of side effects. Dr. Ulrich’s group has 
used pharmacogenomics approaches to uncover a specific genotype that 
reduces the risk of colorectal cancer upon regular aspirin use and a genotype 
that does not benefit from long term aspirin use. The group is now working on 
better understanding the cost effectiveness of using genotype-guided aspirin use 
as a primary chemoprevention method in colorectal cancer versus standard 
colonoscopy screening. Dr. Ulrich plans to translate these findings into the clinic 
to stratify patients at risk for colorectal cancer into groups that will benefit from 
																																																								
13 E. Flossmann, P.M. Rothwell, British Doctors Aspirin Trial & the UK-TIA Aspirin Trial, Effect of 
aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and 
observational studies, 369 Lancet 1603 (2007). 
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aspirin use and those that will not, and to develop a blood test that would allow 
people at risk for colorectal cancer and their clinicians to make informed 
decisions on whether the benefits of long term aspirin use outweigh its risks. 
  
Next, Dr. Ulrike Peters discussed her group’s efforts to personalize risk 
prediction for colorectal cancer. Colorectal cancer is the 3rd leading cause of 
cancer-related deaths in the US, and, although very effective screening tools 
already exist, approximately one-third of the eligible US population has not 
received this screening. In fact, because current guidelines are only based on 
age and family history, rates of colorectal cancer are on the rise in populations 
that do not meet screening criteria. The goal of Dr. Peters’ group is to create a 
comprehensive risk prediction model to stratify people in high risk groups for both 
screening and intervention. To realize this goal, Dr. Peters utilizes the large 
datasets available through the Genetics and Epidemiology of Colorectal Cancer 
Consortium (GECCO). GECCO is a consortium of investigators from multiple 
institutions that aggregates data from studies.  GECCO allows Dr. Peters’ group 
to use genetic information coupled with epidemiological and environmental 
information from these studies to innovate new statistical methods for risk 
prediction. The risk prediction model being developed takes into consideration 
the following variables: age, family history of colorectal cancer, sex, a genetic risk 
score, and an environmental risk score while adjusting for endoscopy. Applying 
this model to a study cohort of ~8,000 cases and ~9,000 controls showed that 
incorporation of the genetic and environmental risk scores increases their ability 
to accurately predict colorectal cancer risk. Dr. Peters is also using this risk 
prediction model to inform the age at which an individual would benefit from 
screening, thus predicting the appropriate age based on the individual’s risk to 
start receiving the life-saving colorectal cancer screening.  The next step in this 
work is to bring personalized screening into public health practice and clinical 
care. To do so, the risk prediction modeling will need to be further tested in a 
community based setting and used to predict earlier stages of disease. In 
addition, the model needs to be subjected to validation and cost effectiveness 
studies, culminating in a clinical trial to show its utility in colorectal cancer 
prevention. 
  
Dr. Marc Lenburg then described his work in the area of precision lung cancer 
prevention. Lung cancer is the second leading cancer diagnosis and the leading 
cause of cancer death in the US. However, early detection of lung cancer 
through screening is known to reduce mortality of this disease.14,15  Screening for 
lung cancer by imaging is the most common technique, but this approach leads 
to high rates of false positives, and only 4% of individuals showing abnormal lung 
masses by imaging actually have lung cancer. A definitive lung cancer diagnosis 
																																																								
14	C.F.	Mountain, A new international staging system for lung cancer. 89 Chest 225S (1986). 
15 National Lung Screening Trial Research, et al. Reduced lung-cancer mortality with low-dose 
computed tomographic screening. 365 N. Engl. J. Med 395 (2011). 
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requires the examination of tissue pathology, which is obtained through an 
invasive diagnostic procedure such as bronchoscopy, needle biopsy, or surgical 
resection. Therefore, precision prevention of this disease requires the integration 
of molecular information to guide the diagnostic workup and prevent unnecessary 
invasive procedures.  
 
The group’s early work in this area utilized expression profiling of genes 
expressed in bronchial tissue to develop a predictive biomarker. The team 
analyzed gene expression profiles in samples from normal appearing cells 
collected during bronchoscopy and identified a panel of 80 genes showing 
different patterns of gene expression from normal vs. diseased cells.16  This 
approach was validated in a clinical trial17,18 and is now utilized clinically to 
differentiate individuals who only need further monitoring from those who require 
more invasive diagnostic procedures to definitively identify whether a mass is 
cancer or not. Dr. Lenburg and his team are now moving toward identifying a 
tissue source that is even less invasive and costly than collecting bronchial 
tissue. Their studies have focused on cells from nasal tissue collected through a 
nasal swab based on the theory that if the entire respiratory tract is affected by 
lung cancer disease processes, then these processes may be detectable 
molecularly in a tissue type that is more accessible than bronchial tissue. Current 
work has identified a molecular signature and has shown that adding the 
molecular information on top of the clinical information leads to improvements in 
diagnostic sensitivity.19  Taken together, this work is leading to less invasive, 
more cost-effective mechanisms to detect lung cancer early and accurately to 
ensure that the people who need treatment are getting it as soon as possible, 




2.  Catalyzing Translational Innovation 
 
Dr. Chris Austin, director of the National Center for Advancing 
Translational Sciences at NIH (NCATS) addressed the topic of personalized 
medicine from the perspectives of both key national initiatives and a broader 
institutional effort at NIH.  President Obama’s State of the Union address in 2015 
introduced the Precision Medicine Initiative as an important platform by which the 
U.S. could more deeply understand variations in individual responses to 
																																																								
16 A. Spira, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with 
suspect lung cancer. 13 Nat. Med. 361 (2007). 
17 G.A. Silvestri, et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung 
Cancer. 373 N. Engl. J. Med. 243 (2015). 
18 D.H. Whitney, et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective 
study of patients undergoing diagnostic bronchoscopy. 8 BMC Med Genomics18 (2015). 
19  J.F. Perez-Rogers, et al. Shared Gene Expression Alterations in Nasal and Bronchial 
Epithelium for Lung Cancer Detection. 109 Jnci-J Natl Cancer I (2017). 
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therapeutic interventions; gain health insights through discoveries made possible 
by genetic and genomic advances; help address deficiencies in studying under-
represented populations; and use modern technologies such as mobile sensors 
to better monitor health status.  The original design--to enroll a cohort of one 
million individuals who would be followed longitudinally over a number of 
decades—is now being realized as the “All of Us” study.20 In addition to the data 
and information derived from this cohort, there are important goals to improve the 
culture and environment of clinical research in the US by improving the quality of 
informed consent; better data sharing; and more assiduous response to 
participant inquiries and return of clinical data results.  One year later, an 
initiative, the “Cancer Moonshot”, to accelerate the progress of discovery in 
oncology was announced.  Its goals are similar, namely to accelerate discovery 
and improve individual patient care through either better targeted therapies or 
stratification to enhance preventive testing. Key facets of the initiative include the 
importance of direct patient involvement; team science and national networks in 
a variety of disciplines including immunotherapy, overcoming cancer resistance, 
and systematic approach to childhood cancers.   
 
In many ways, these two initiatives are an extension of the NIH focus on 
improving translational research—namely getting basic discoveries to the public--
-and is the remit of NCATS.  NCATS has a two-fold goal: making fundamental 
discoveries to treat diseases, like its efforts in rare diseases that afflict 
approximately 25 million Americans, and improving the science of translation, 
namely applying the scientific method of evaluating processes and scientific 
platforms to improve clinical research.  Dr. Austin identified the broader societal 
problem that NCATS attempts to address as follows: As a biomedical community, 
we are making major scientific advances at the discovery bench, and due to 
advances in technology, are poised to make even more discoveries directed to 
understanding the genetic basis for thousands of rare diseases.  Unfortunately, 
our antiquated processes to translate these basic discoveries to improvements in 
clinical care greatly delay the possibilities of enhancing the impact of discoveries 
on broader public health.  Thus, Dr. Austin has focused NCATS on improving 
both the processes and culture of translational research, with full awareness that 
quantum advances are more important than small incremental improvements.  
Two such process improvements and innovations include: (1) better utilization of 
available libraries of small molecules and information about their pharmacology 
profiles to identify potential treatments for rare diseases; and (2) developing tools 
better to predict the potential toxicities of potential new therapies.   
 
The CTSA (Clinical and Translational Science Award) program is one of 
the centerpieces of NCATS’s efforts, and supports translational research efforts 
in approximately 60 academic medical centers.   The program seeks to help 
improve the culture of translational research by rewarding team science and 
collaboration, in addition to supporting other vital goals such as training the next 
																																																								
20 https://allofus.nih.gov/. Accessed 11/7/2017 
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generation of biomedical scientists, and emphasizing the importance of deep 
community engagement and patient-centered research.  One area of immediate 
priority is to establish an effective consortium of the CTSA centers (called the 
Trial Innovation Network) which can readily participate in multi-center clinical 
trials by making the trial planning and initiation processes more efficient through 
various measures such as single IRB approval and improved contracting.21  
 
3.  The Public And Precision Medicine 
 
a.  Recruiting Large Research Cohorts 
 
The ambitious plan of the “All of Us” Research Program is to recruit 1,000,000 
or more American volunteers who will provide researchers with access to their 
genetic information, their environmental exposures and activities, and their 
electronic medical records, all with the aim of understanding how genetic 
predispositions, environmental exposures, and lifestyle choices contribute to 
health and disease. This program has been praised for its ambitious size and 
scope, its tremendous clinical promise, and its daunting set of scientific, 
technological, and ethical-legal challenges.  
 
The combination of excitement and trepidation surrounding the All of Us 
Research Program might give some the impression that it is the first effort to 
create a large, longitudinal research cohort designed to investigate genetic and 
environmental impacts on health. In fact, however, a number of regional, 
national, and international programs have been created in the last 15 years with 
precisely that design and purpose. As the United States embarks on the next 
national cohort, there are valuable lessons to be learned from others who have 
already gone down that path. This session sought to gain insights from two 
researchers who have been intimately involved with efforts in the United States 
(one public, one private) to create large, longitudinal research cohorts. Laurence 
Meyer discussed the Million Veterans Program that is housed in the Veterans 
Administration (VA). Catherine Schaefer described the Research Program on 
Genes, Environment and Health run by Kaiser Permanente Northern California 
(KPNC). Challenges, foci, and lessons common to both programs were 
particularly insightful.    
 
The Million Veterans Program was conceived over a decade ago when 
researchers at the VA realized that they had access to a tremendous resource in 
the millions of veterans receiving healthcare through the VA medical system. The 
VA developed one of the first electronic medical record systems in the world, and 
was thus in a strong position to link genetic/environmental/lifestyle information 
about their patients with the electronic medical records of those patients which go 
back decades. The Research Program on Genes, Environment, and Health was 
developed by geneticists and epidemiologists at KPNC in the early-2000s. Like 
																																																								
21 https://ncats.nih.gov/ctsa. Accessed 11/7/2017 
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the researchers at the VA, the KPNC researchers realized that the 3.3 million 
members receiving their healthcare through the health delivery system offered a 
remarkable potential data set for investigators. Both programs have already 
enrolled several hundred thousand participants, and both have been utilized for a 
variety of research projects (e.g. a genome-wide association study of 
schizophrenia by the VA, and a genome-wide association study of bipolar 
disorder by KPNC). 
 
There are striking similarities regarding challenges, foci, and lessons faced by 
these two large, longitudinal cohort programs: 
 
Underrepresentation of Young Adults: Both programs struggled to enroll 
younger participants (i.e. ages 18-39). The population of the cohorts both skewed 
older than the U.S. population. The reasons for lower enrollment among younger 
individuals was a topic of speculation—perhaps younger people are more 
busy/distracted and so less likely to enroll. Regardless, the underrepresentation 
among younger participants is a potential concern for cohort designers and 
researchers. If researchers are interested in investigating conditions with early-
adult onset, then it will be important to ensure there are sufficient representatives 
from that group to support that research.  
 
Data Management: Both programs encountered significant challenges 
associated with managing the data from the cohorts (see also the discussion in 
Part I.b, above). Some of these challenges arose from trying to take the 
information in electronic medical records, which are designed primarily for the 
care of patients, and translating/distilling that into standardized information that 
can be quantified and tracked for research purposes. Other challenges arose 
from the sheer quantity of data. A single participant can create dozens of data 
points from a single questionnaire. When that information is combined with an 
electronic medical record, the number of data points jumps to the thousands. 
Finally, when genetic information about that participant is figured in, it can 
become millions of data points. And that’s just for one participant. When that is 
multiplied by the several hundred thousand or million participants in the entire 
cohort, the amount of data becomes logistically and technologically daunting. 
The VA found this challenge so severe that it had to team up with the 
Department of Energy in order to access the computing power necessary to 
handle the data. That resource, of course, will not be available to all research 
cohorts. 
 
Genetic Focus: Both cohort programs professed an interest in supporting 
research on the genetic, environmental, and lifestyle contributions to health and 
illness. And yet, the design and performance of both programs indicated a 
stronger genetic focus. When giving examples of research supported by the 
programs, for example, both Meyer and Schaefer discussed genome-wide 
association studies. To be clear: this is not to suggest that the researchers 
themselves have a genetic bias. Rather, it is most likely a result of the fact that 
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genetic information is much easier to get and analyze than 
environmental/lifestyle information. A simple blood or saliva sample can provide 
material for producing an individual’s entire human genome. Information about 
that same person’s environment and their lifestyle, on the other hand, is much 
more difficult to acquire and assess. The cohort programs at the VA and KPNC 
both relied in part on questionnaires/surveys administered to their participants to 
gather information about lifestyle, but those methods are notoriously unreliable. 
Getting objective data about environmental exposures and lifestyle decisions 
(with things like wearable monitors, in-home monitoring devices, and geocoded 
databases that link participants’ locations with information about environmental 
factors in those areas) is more difficult and more expensive. Until measuring the 
environment in a reliable way becomes easier and cheaper, these large, 
longitudinal research cohorts will continue to produce more information about 
genetic contributions to health/disease than environmental/lifestyle contributions 
to those same conditions.  
 
Early Community Involvement: Both Meyer and Schaefer emphasized the 
importance of getting input from potential participants at the very earliest stages 
of cohort creation. The first step in the Million Veterans Program was to ask 
veterans affiliated with the VA what they would want the cohort to look like. 
Similarly, the program at KPNC created a community advisory board early on in 
order to get its advice. Formally implementing this community-input step early is 
important because it gives potential participants the opportunity to shape the 
cohort program from its inception—to contribute to decisions about what sorts of 
research questions the cohort can be designed to answer, what sorts of 
motivations make participating attractive, and what sorts of concerns about 
participation disincline someone from enrolling.  
 
The differences between the Million Veterans Program at the VA and the 
Research Program on Genes, Environment, and Health at KPNC are quite 
striking. One is a federal program made up entirely of veterans. The other is a 
private program made up entirely of patients/members affiliated with a national 
health care delivery system. And yet, both programs encountered similar 
challenges (of underrepresented young adults, of data management), produced 
similar research results (focused mainly on genetics), and offered similar lessons 
(about the importance of involving the community of potential participants early in 
the decision-making process). The fact that these similarities occurred despite 
the differences in the programs suggests that they are general features that any 
large, longitudinal research cohort can face. As the United States embarks on a 
new, national cohort—the Precision Medicine Initiative’s All of Us Research 
Program—insights from the large, longitudinal cohorts at the VA and KPNC are 
likely to prove invaluable.    
 
 
Precision Medicine II  Page 15 
b. Engaging The Public In The Program 
 
This session addressed prevalent challenges shared by both the public and 
professionals with the communication and interpretation of genetic information 
and the informed consent process.  Dr. Kimberly Kaphingst emphasized the 
prevalence of low health literacy in the general population in the US, noting 
particular challenges for minority populations, older individuals, and individuals 
with lower educational attainment.  For example, data suggest that almost half of 
individuals with less than high school or some high school education have a 
below basic level of health literacy. The implication is that professional efforts to 
communicate complex information to patients must be sensitive to the low levels 
of background health literacy that are common in the population.  Dr. Kaphingst 
also highlighted the difficulties and current inadequacies in obtaining informed 
consent for research such as for biobank participation.  The average reading 
level of the US population is at the 8 – 9th grade level yet consent forms are often 
written at a college reading level.  The presentation addressed a number of 
efforts documented in the literature to improve the content and process of 
informed consent.  These include communication strategies such as simplified 
language, clear organization, descriptive headings, illustrations, and new formats 
such as videos.  Further, she emphasized need to think beyond the form to 
consider enhanced processes involving better training for professionals, more 
extended dialogue with patients or research participants, and measures to 
assess comprehension.  Dr. Kaphingst suggested that there will be no easy 
solutions to these challenges but work along a number of avenues to use and 
assess better communication strategies will be valuable.  
 
Dr. Angela Fagerlin next addressed a set of challenges in the flow of genetic 
information between the laboratory, the health professional, and the patient.  A 
particular problem in the current state of genetic knowledge is our inability to 
provide clear interpretations of many genetic variants identified through testing.  
A second set of issues arises from the limited knowledge and experience of 
many health care professionals with respect to ordering and interpreting genetic 
tests.  Data suggest that providers themselves recognize their limits in this 
respect and have a low level of confidence in their abilities.  Individuals who 
obtain genetic information through DTC sources often choose not to share these 
results with their physicians because they lack confidence in the ability of their 
physician to interpret the information.  Several measures have been assessed to 
enhance communication of risk-related results between physicians and patients 
including different types of graphic presentations.  Data indicate that these 
measures can impact interpretations of risk.  Dr. Fagerlin also addressed public 
attitudes about several significant ethical issues in genetic testing, including the 
appropriate disclosure of medically actionable results, testing children for adult 
onset conditions, and the disclosure of carrier status.  Data suggest that lay 
individuals will change their opinions to conform more closely with current 
professional standards when they are provided information about the ethical 
concerns in these domains.  This session emphasized the significant challenges 
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and barriers to precision medicine arising from the background knowledge of 
both professionals and the public and the need for more effective communication 
strategies to deal with this complex information.  
 
c.  The Ethics of Access and Precision Medicine 
 
The million lives cohort, as planned for the cancer moonshot and the 
precision medicine initiative more generally, raises significant issues of justice.  
These issues will include recruitment of cohort members, informed consent by 
cohort members, participation of cohort members in decisions about data 
collection and use, data sharing, communication of findings based on cohort 
data, and the ultimate availability of benefits from research discoveries.  
Panelists Jessica Roberts and Dr. Maya Sabatello discussed several of these 
important issues. 
 
Professor Roberts’s presentation considered downstream and upstream 
access issues.  Downstream access issues, such as who will have access to the 
benefits of the precision medicine initiative are surely important.  Benefits such 
as individualized forms of cancer treatment can be expected to be very costly. 
But Roberts also emphasized the importance of considering upstream barriers to 
access.  Such barriers might be built into the rules, algorithms, and reference 
databases that make up the precision medicine initiative, Prof. Roberts said.  If 
the information that is collected from participants in the million lives cohort 
includes genetic information and clinical information but leaves aside housing, 
community safety, employment status, environmental exposures, immigration 
status, or available services, it may focus myopically in medical information and 
ignore potentially critical roles of the social determinants of health.  If certain 
groups are underrepresented in the research, results pertaining to them may be 
less accurate as well. 
 
The precision medicine initiative is a very expensive enterprise, Roberts 
emphasized.  It may consume a great deal of research resources and is, itself a 
“resource allocation” decision.  As such, it is especially important to scrutinize 
diseases to be studied, research questions to be asked, and who is more likely to 
benefit from the perspective of justice. Prof. Roberts also raised the concern that 
historical participation in medical research has been skewed by race and 
ethnicity; it will be important that the precision medicine initiative do a better job 
of addressing this issue. It will not be easy; African-Americans particularly are 
less likely to trust participation in research because of the legacy of Tuskegee 
and the more recent telling of the story of Henrietta Lacks.22 
 
Prof. Roberts’ takeaways to the audience were first, that access issues in 
precision medicine reach far beyond who has the benefit of using the end 
product, to the relative benefits and accuracy of the research for affected 
																																																								
22 Rebecca Skloot, The Immortal Life of Henrietta Lacks (2010). 
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populations, and second, that the initiative must fund research on conditions 
affecting a variety of populations and build the trust needed to recruit diverse 
research participants. 
 
Dr. Sabatello’s talk addressed issues for persons with disabilities raised by 
the precision medicine initiative. She began by pointing out that although 22% of 
US adults and 13% of US children have disabilities, disability to date has not 
received much discussion in the precision medicine initiative.  
 
To the extent that disabilities are genetic in origin, they will be subject to 
disability rights criticisms of genetic research. These include genetic essentialism 
and the sorry history of eugenics. Some forms of pre-natal testing, pre-
implantation genetic analysis, or postnatal predictive and diagnostic testing may 
reveal discriminatory attitudes such as the devaluation of lives with disabilities or 
the presentation of unjustifiably negative prognoses.  Disability rights critics point 
to the wide variety of disability and to how the geneticization of impairment may 
direct attention and budgetary allotments to medical interventions rather than to 
the social and environmental factors that cause or contribute to disability.  
Precision medicine has the promise to be attuned to the social model of 
disability—how social factors contribute to the impact of disabilities on peoples’ 
lives—but only if it is constructed to take these factors into account. 
 
Despite the universality of disability, moreover, people with disabilities 
continue to experience significant health disparities and disparities in access to 
care.  There are high rates of co-morbidity that are not well understood, such as 
increased risks of epilepsy and Parkinson’s disease among people with 
intellectual disabilities, and variant cancer rates among people with 
schizophrenia. Physical barriers such as inaccessible clinic design or diagnostic 
equipment remain problems.  People with disabilities are less likely to participate 
in clinical trials.  They are also less likely to have private health insurance and 
instead to be dependent on Medicaid or Medicare for payment for their care—or 
to forego health care instead. 
 
Dr. Sabatello then emphasized the importance of making information about 
the precision medicine initiative available to people with disabilities.  Accessible 
information about participation, such as publicity in Braille or in plain language, is 
critical.  So is reconsideration of informed consent requirements and processes, 
so as not to exclude populations of people with disabilities who might not be able 
to sign or understand standard consent forms. Inclusion of people with 
psychiatric disabilities may also be an issue from the perspective of informed 
consent.  Another concern will be how to deal with how people change and 
acquire disability over the long course of the precision medicine initiative.  It will 
be important to consider information and consent as the initiative develops, so 
that people are not improperly dropped from the cohort or included when they 
would choose not to continue. 
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In sum, the precision medicine initiative will require continued attention to 
issues of justice, from its beginnings in the questions asked and populations 
enrolled, to its endpoints in research discoveries and their translation into 
improvements in patient care and public health.   These are not static questions 
or answers, but will change and develop over time. 
	
4.  The Economics of Precision Medicine 
 
a.  Patenting And Precision Medicine 
 
 Patents have traditionally given the developers of diagnostic and 
therapeutic products a period of exclusivity (20 years in the United States and 
most other countries) during which to use those products free from market 
competition.  On one hand, the exclusivity afforded by patent protection enables 
inventors to charge rates for their products that offset the significant costs of 
product development and regulatory approval (estimated to be in excess of one 
billion dollars for a typical pharmaceutical product). On the other hand, the 
pharmaceutical industry has been criticized for charging excessive rates that 
make life-saving drugs unaffordable to many, both in the U.S. and abroad 
(particularly in the developing world). In general, critics of the patent system have 
alleged that the issuance of too many patents in areas of biomedical research 
can impede research and scientific progress.23  
 
 The development of precision medicine therapies has complicated the 
patent landscape, with recent Supreme Court decisions casting doubt on the 
degree to which such innovations are eligible for patent protection at all. This 
panel explored a range of issues relating to the patentability of precision 
medicine techniques, the potential impact of recent judicial decisions on 
protection offered by the patent system, the effect of patents on biomedical 
research at academic institutions and elsewhere, and policy and public health 
considerations surrounding all of these issues. 
 
 Jorge Contreras introduced this session with an overview of the statutory 
and judicial state of the law surrounding patent eligibility in the United States. 
Section 101 of the U.S. Patent Act provides that “Whoever invents or discovers 
any new and useful process, machine, manufacture, or composition of matter … 
may obtain a patent therefor.”24  While this definition can be applied in a relatively 
straightforward manner to inventions involving new mechanical devices, serious 
questions of patent eligibility arise when an inventor seeks to claim something 
derived from the natural world (a so-called “product of nature”), or something that 
is in essence an abstract idea or mental process. Traditionally, courts have held 
																																																								
23 Mark A. Heller and Rebecca S. Eisenberg, Can patents deter innovation? The anticommons in 
biomedical research. 280 Science 698 (1998). 
24 35 U.S.C. Sec. 101. 
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that neither products of nature, abstract ideas nor mental processes are eligible 
for patent protection. 
 
 These patentability exclusions have recently been put to the test in the 
context of biomedical innovation.  Beginning with the seminal case Diamond v. 
Chakrabarty in 1980,25 the U.S. Supreme Court recognized the patentability of 
man-made biological organisms (in this case, a bacterium customized to break 
down crude oil). Based on the Chakrabarty decision, the U.S. Patent and 
Trademark office (PTO) began to allow patents on biological entities. This 
practice became particularly controversial in the area of human DNA. Beginning 
in the early 1990s, researchers began to seek patent protection for newly-
discovered DNA sequences. Among the most controversial of these were patents 
obtained by Myriad Genetics and the University of Utah on the BRCA1 and 
BRCA2 genes, as well as certain mutations to those genes that indicated 
substantially elevated risk for breast and ovarian cancer. The BRCA patents 
were challenged in a 2009 lawsuit, which alleged that they covered products of 
nature that were ineligible for patent protection.26  In 2013, the Supreme Court 
invalidated most of the challenged patent claims, holding that human DNA, even 
if isolated and purified in the laboratory, constituted a product of nature that was 
not patentable subject matter.27 
 
 Even more relevant for precision medicine are individualized treatment 
regimens based on patient physiology and responses. In 2006, three justices of 
the Supreme Court hinted that they were skeptical of patents claiming such 
diagnostic methods.28 However, it was not until 2012, in Mayo v. Prometheus,29 
that the Court squarely considered the patentability of a personalized medical 
treatment.  In Mayo, the challenged patent claimed a method of determining the 
optimal dosage of thiopurine (a drug for an immune-mediated gastrointestinal 
disorder) by monitoring the level of 6-thioguanine (a metabolite of thiopurine) in a 
patient’s blood after administration of the drug. If metabolite levels were below a 
certain level, the thiopurine dosage should be increased, and vice versa. The 
Court, in holding that the claimed subject matter was not patent eligible, 
reasoned that the relationship between metabolite levels and drug efficacy is a 
“law of nature”, and that a patent should not be granted unless the inventor adds 
“additional features” beyond that basic natural law. Moreover, the physician’s 
																																																								
25 447 U.S. 303, 317-18 (1980). 
26 For a detailed account of the BRCA litigation see, e.g., Jorge L. Contreras, Narratives of Gene 
Patenting, 43 FLA. ST. L. REV. 1133 (2016), and Sandra S. Park, Gene Patents and the Public 
Interest: Litigating Association for Molecular Pathology v. Myriad Genetics and Lessons Moving 
Forward, 15 N.C. J.L. & TECH. 519 (2014). 
27 133 S. Ct. 2107 (2013).  The Court also held, however, that man-made DNA segments (e.g., 
cDNA), even if replicating the sequence of naturally-occurring DNA, were eligible for patent 
protection. 
28  Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. 548 U.S. 124 (2006) (dissent to denial of 
certiorari). 
29 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012). 
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observation of metabolite levels in the blood and decision to alter the patient’s 
thiopurine dosage on that basis, is simply a mental process. Thus, because the 
claimed invention simply relied on an observation of a natural relationship and a 
corresponding alteration of the patient’s drug dosage, the patent was found to be 
invalid. 
 
 Bernard Chao, in a talk entitled “Measuring the Mayo Effect,” began by 
noting many of the dire predictions made by commentators following the Mayo 
decision. These commentators predicted that in the wake of Mayo, many 
personalized medicine technologies would no longer be patentable, thereby 
causing serious problems for the medical diagnostics industry and potentially 
reducing innovation in this field.30 To test these predictions empirically, Prof. 
Chao and collaborators measured the number of precision medicine patent 
applications rejected by the PTO from 2006 through 2016, a ten-year period 
spanning the issuance of the Mayo decision.  Based on a sample of 10% of the 
total set of patent applications filed in the relevant technology class, they found 
that PTO rejection of applications based on Section 101 patent eligibility grounds 
increased dramatically, from 15.9% prior to the Mayo case to 86.4% after 
Mayo. 31  He also described a subsequent study in which the investigators 
compared Section 101 patent eligibility rejections across ten different technology 
classes.  They found the highest rate of such rejections in the class pertaining to 
precision medicine.  Further studies are being planned to obtain more detailed 
data on these rejections and their impact. 
 
 Colleen Chien also addressed the impact of Mayo and a related 2010 
patent eligibility case, Bilski,32 in a talk discussing work conducted with Arti Rai of 
Duke University.  Professors Chien and Rai sought to understand the impact of 
patentability limitations on innovation in the medical diagnostics industry. They 
found that in the area of biomarker-based diagnostics, patent application filings 
(which are viewed as proxies for innovation) dipped immediately after the Mayo 
case, but have recovered since then, suggesting that firms have developed 
effective strategies for overcoming Section 101 eligibility rejections in this field.  
Likewise, they found that Mayo had no significant impact on either the size of 
firms patenting in the area of diagnostics or the number of commercial 
transactions conducted in the diagnostics industry (which increased sharply after 
2012).  However, based on measurable increases in the word length of patent 
claims, they hypothesize that the scope of patent protection in the diagnostics 
																																																								
30 See, e.g., Arti Rai, Biomedical Patents at the Supreme Court: A Path Forward , 66 Stan. L. 
Rev. Online 111 (2013), Christopher Holman Mayo, Myriad, and the Future of Innovation in 
Molecular  Diagnostics and Personalized Medicine, 15 N.C. J. L. & TECH. 639, 677 (2014), 
Rebecca S. Eisenberg, Diagnostics Need Not Apply, 21 B.U. J. SCI. & TECH. L. 256, 285 (2015). 
31 Bernard Chao and Amy Mapes, An Early Look at Mayo’s Impact on Personalized Medicine 
Patenting, Patently-O blog (April 4 2016), http://patentlyo.com/lawjournal/2016/04/personalized-
medicine-patenting.html.  See also Heidi Ledford, US Personalized Medicine Industry Takes Hit 
from Supreme Court, 536 Nature 382 (2016). 
32 Bilski v. Kappos, 561 U.S. 593 (2010). 
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field has narrowed since Mayo, as firms have been required to add additional 
limitations to their patent claims in order to overcome Section 101 rejections. 
They conclude that, notwithstanding many predictions, innovation in the field of 
biomarker-based diagnostics has increased, not declined, since Mayo. 
 
 Next, Kshitij Kumar Singh offered an international perspective on precision 
medicine patenting with a particular focus on India.  He first noted a number of 
challenges facing India and other developing countries in the area of healthcare, 
notably the affordability and accessibility of advanced medical technologies and 
treatments, the difficulties of a large and disorganized health and insurance 
sector, and a fragmented research landscape. Given these challenges, coupled 
with the dominance of foreign firms in the biopharmaceutical industry, policy 
makers in India have become wary of intellectual property protection for 
biomedical products.  Accordingly, as permitted under the TRIPS Agreement,33 
the Indian Patent Act prohibits the patenting of “any process for the medicinal, 
surgical, curative, prophylactic [diagnostic, therapeutic] or other treatment of 
human beings or any process for a similar treatment of animals to render them 
free of disease or to increase their economic value or that of their products.”34 
However, he also noted that if an invention includes a novel biomarker or 
detection method, there may be ways to pursue patent protection. The impact of 
such policies on both foreign firms seeking to enter markets in developing 
countries, as well as local innovators in those countries, will be important as 
policy makers in developing countries continue to refine their local legal 
structures to address emerging technologies in the field of precision medicine.35 
  
 In the final presentation of this session, Shubha Ghosh discussed the 
current policy landscape pertaining to precision medicine, big data and 
intellectual property.36 He observed the increasing emphasis on data extraction 
and analysis in the biomedical field, which has been coupled with increasing 
patenting in this area. He also examined current administration proposals in 
areas including Medicaid/Medicare reform and competition law enforcement and 
their potential impact on innovation.  He then questioned whether incremental 
innovation in U.S. precision medicine will be likely in view of the current policy 
and political landscape. Ultimately, he concluded, incentives must be available to 
encourage innovation, though these incentives may arise from mechanisms other 
than patent law. 
 
																																																								
33  Article 27.3 (a) gives Member Nations of WTO an option to exclude from patentability 
"diagnostic, therapeutic and surgical methods for the treatment of humans or animals  
34 Indian Patents Act 1970, amended 2005, Sec. 3(i). 
35 See, generally, Kshitij Kumar Singh, Biotechnology and Intellectual Property Rights: Legal and 
Social Implications (Springer, 2015). 
36 See, generally, Shubha Ghosh, Identity, Invention, and the Culture of Personalized Medicine 
Patenting (Cambridge Univ. Press, 2013). 
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b.  Providers, Payers, and Laboratory Testing 
 
In the final session, Dr. Diana Brixner introduced the audience to the 
complex world of reimbursement from a payer perspective.  There has been 
explosive growth in the number of specialty, frequently expensive drugs, which is 
differentiated from those—generally small molecules or pills—used in primary 
care for complex chronic disorders.  The overall proportion of the pharmaceutical 
budget devoted to specialty drugs has similarly increased, posing a growing 
dilemma for payers on how to pay for these drugs through insurance without 
increasing member premiums.  One tool for assessment of these new, expensive 
drugs is to balance the differential benefit against the differential cost. 
 
Different professional groups are attempting to grapple with measuring 
“value” of therapeutic interventions being used by practitioners.  NCCN (National 
Comprehensive Cancer Network) and ASCO (American Society of Clinical 
Oncology) are two major examples for oncology. NCCN provides a grade of 1 
(weak) to 5 (strong) for available clinical evidence on key parameters of efficacy; 
safety; availability of comparative data; consistency of data; and affordability, 
related to drug-acquisition cost.  ASCO utilizes a value framework in evaluating 
the clinical benefit of cancer treatments against their costs and toxicity.  
Conceptually, there is an attempt to compare the net benefits (improvement in 
survival vs. toxicity of therapy) of two comparative regimens to identify the 
intervention of greater value.  Another society—ICER (Institute for Clinical and 
Economic Review, not to be confused with the same acronym which denotes 
incremental cost-effectiveness ratio)—seeks to attain sustainable high-value care 
for all patients.  Its value framework evaluates long-term value-for-money 
assessments based on incremental and comparative cost-effectiveness, and 
short-term affordability as assessed by budget impact.  As information on value 
become more available, innovative contracting approaches are evolving. For 
example payers may be reimbursed by the drug manufacturer if specific clinical 
outcomes are not achieved from the therapeutic intervention, called “outcomes-
based contracting”. For drug interventions that require a significant initial 
payment, for example Solvadi in treating and potentially curing hepatitis C, the 
initial cost can be shared by the initial and future payers.  Personalized medicine 
will play a larger role in defining the health plan population that will receive the 
greatest benefit from these new therapies. 
 
Payers are also assessing different ways of contracting with health care 
providers.  These include contracting and reimbursing for management of a 
disease rather for individual drugs 
 
Dr. Christopher Corless outlined the promise that a deeper molecular 
understanding of disease—for example the new taxonomy of non-small cell lung 
cancer—and targeted therapies such as ALK-directed medicines are providing to 
stricken patients.  He then delineated the health care provider dilemma: precision 
medicine and targeted therapies require accurate diagnostics, but development 
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and regulatory approval of both the therapy and the diagnostic test are commonly 
asynchronous, and reimbursement approval is haphazard and insufficient to 
compensate for the major laboratory investments required to handle biological 
samples and analyses.  Hence cumbersome barriers frequently confront both 
patient and provider. 
 
A more logical manner of reimbursement in oncology is an urgent need.  
The burgeoning field of immuno-oncology will require laboratories to evaluate 
both tumor samples and the patient’s own immune system.  Furthermore, 
following cancer patients over time ideally requires both extensive initial 
evaluation of the tumor and its microenvironment but also metastatic lesions or 
chemotherapy-unresponsive tumors.  Finally, advances in other “–omics” 
technologies and the increasing data load requires great technical expertise and 
is costly.   
 
Dr. Craig Nichols concluded with a historical perspective on advances in 
precision medicine.  He cautioned the audience to recognize the potential 
limitations of new therapeutic interventions, the duration of time required for 
incorporation of medical advances into clinical practice, and importance of the 
breadth of factors (medical, genetics, socio-economic, environmental) that impact 
an individual’s health and well-being.  Finally, he emphasized the importance of 






Precision medicine is being developed within a complex landscape of 
public policy, science, economics, law, and regulation. In these and other policy 
areas, the goal of developing individually-tailored therapies poses novel 
challenges for health care research, delivery and policy. In this symposium, a 
range of experts in genetics, medicine, bioinformatics, intellectual property,  
health economics and bioethics identified and discussed many of the 
pressing questions raised by the development and practice of precision 
medicine. These and other issues will need to be taken into account as precision 
medicine moves ahead and becomes the standard of medical practice and care 
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Thursday, December 1, 2016 
 
 
1. Tackling Cancer with Precision Data 
 
a. The Science of Precision Oncology 
Moderator: Ana Maria Lopez, M.D., M.P.H., F.A.C.P., Professor of Internal 
Medicine; Associate Vice President for Health Equity and Inclusion; and 
Director of Cancer Health Equity at Huntsman Cancer Institute, University of 
Utah 
Kathleen Cooney, M.D., F.A.C.P., Professor and Chair of Internal Medicine, 
University of Utah 
Scott Tomlins, M.D., Assistant Professor of Genitourinary Pathology, University 
of Michigan 
 
b. The Challenges of Big Data 
Moderator: Kensaku Kawamoto, M.H.S., M.D., Ph.D., University of Utah 
 
Samir Courdy, M.B.A., Huntsman Cancer Institute 
Rakesh Nagarajan, M.D., Ph.D., Founder and Chief Information Officer at 
PierianDx and Adjunct Associate Professor of Pathology and Immunology, 
Washington University in St. Louis 
David Nix, Ph.D., Co-Director of Bioinformatics Shared Resource, Huntsman 
Cancer Institute 
 
c. Precision Prevention 
Moderator: Cornelia Ulrich, M.S., Ph.D., Senior Director of Population Sciences 
at Huntsman Cancer Institute and Division Chief of Population Health Sciences, 
University of Utah 
Ulrike Peters, M.P.H., Ph.D., M.S., Research Professor of Epidemiology, 
University of Washington, Full Member at Fred Hutchinson Cancer Research 
Center 
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Marc Lenburg, Ph.D., Professor of Medicine in the Division of Computational 
Biomedicine, Boston University 
 
2. Keynote Address  
 
Catalyzing Translational Innovation 
Christopher Austin, M.D., Director, National Center for Advancing Translational 
Sciences (NCATS) 
 
3. The Public and Precision Medicine 
 
a. Recruiting Large Research Cohorts 
Moderator: James Tabery, Ph.D., Professor of History and Philosophy of 
Science, University of Utah 
Laurence Meyer, M.D., Ph.D., Veterans Administration Medical Center 
Catherine Schaefer, Ph.D., Kaiser Permanente Division of Research 
 
b. Engaging the Public in the Program 
Moderator: Jeffrey Botkin, M.D., M.P.H., Professor of Pediatrics, University of 
Utah 
Angela Fagerlin, Ph.D., Professor of Population Health Sciences, University of 
Utah 
Kimberly Kaphingst, Sc.D., Health Communication Researcher, University of 
Utah 
 
c. The Ethics of Access and Precision Medicine 
Moderator: Leslie Francis, Ph.D., J.D., Professor of Law and Philosophy, 
University of Utah 
Jessica Roberts, J.D., Director of the Health Law and Policy Institute, University 
of Houston Law Center 




Friday, December 2, 2016 
 
4.  Economics and Precision Medicine 
 
a. Patenting Precision Medicine 
Moderator: Jorge L. Contreras, J.D., Professor of Law, University of Utah 
Bernard Chao, J.D., Associate Professor of Law, University of Denver 
Colleen Chien, J.D., Associate Professor of Law, Santa Clara University 
Shubha Ghosh, J.D., Ph.D., Director of the Technology Commercialization Law 
Center, Professor of Law, Syracuse University 
Kshitj Kumar Singh, Ph.D., Assistant Professor of Law, Amity Institute of 
Advanced Legal Studies 
Precision Medicine II  Page 26 
 
b. Providers, Payer, and Laboratory Testing 
Moderator: Allie Grossmann, M.D., Ph.D., Assistant Professor of Pathology, 
University of Utah 
Diana Brixner, R.Ph., Ph.D., Professor in the Department of Pharmacology, 
University of Utah 
Christopher Corless, M.D., Ph.D., Professor of Pathology, Oregon Health & 
Science University 




Willard Dere, M.D., Professor of Internal Medicine, University of Utah 
Jorge L. Contreras, J.D., Professor of Law, University of Utah 
 
 
